Although PET/CT imaging with PSMA-targeted radiopharmaceuticals has shown remarkable diagnostic capabilities in PCa BCR patients, accurate lesion localization in the initial stages of disease recurrence still poses a significant diagnostic challenge. This evidence concerns the gene FOLH1 and posterior cortical atrophy.